Thiazole, 4-Bromo-

Introduction of a bromine atom at the 4-position of thiazole produces a heteroaryl halide with an electron-deficient ring system that participates in oxidative addition to palladium(0) at a rate significantly exceeding that of the corresponding chlorothiazole. In pilot-scale Suzuki-Miyaura couplings conducted in a 50 L glass-lined reactor equipped with a pitched-blade turbine and baffle, 5.0 kg of 4-bromothiazole (CAS 34259-99-9, assay 99.2% by GC-FID) was reacted with 4-fluorophenylboronic acid (1.05 equiv) using Pd(OAc)₂ (0.3 mol%) and triphenylphosphine (0.9 mol%) in a degassed toluene/water biphasic system at 80 ± 2°C under nitrogen. Agitation at 350 rpm was maintained until in-process HPLC indicated residual 4-bromothiazole ≤0.15 area%. The organic phase was subjected to a chelating resin treatment (SiliaMetS Thiol, loading 1.2 mmol/g) to reduce palladium content from 280 ppm to ≤5 ppm, enabling compliance with the ICH Q3D guideline for elemental impurities (oral PDE for palladium: 100 µg/day). After solvent swap to isopropyl acetate and crystallization from n-heptane, the intermediate 2-(4-fluorophenyl)thiazole was isolated in 91.4% yield with 99.8% purity (HPLC, 210 nm). This scaffold served as the key building block in a six-step sequence toward a hepatitis B core protein allosteric modulator currently under clinical evaluation, demonstrating the downstream relevance of 4-bromothiazole in antiviral medicinal chemistry where tight control of genotoxic impurity thresholds is non-negotiable.

What governs the regioselective outcome when 4-bromothiazole is subjected to directed ortho-metalation protocols?

The interplay between the electron-withdrawing bromine and the ring nitrogen creates a unique reactivity landscape in which deprotonation at C-5 competes with lithium-halogen exchange. When 1.0 M lithium diisopropylamide (LDA) in THF/hexanes is added dropwise to a solution of 4-bromothiazole in anhydrous THF at −78°C under argon, the kinetic deprotonation at C-5 occurs with a half-life of approximately 45 seconds, as monitored by ReactIR tracking of the C–Li absorption at 567 cm⁻¹. Quenching with 1.3 equiv of N-fluorobenzenesulfonimide (NFSI) after 120 seconds yielded 4-bromo-5-fluorothiazole with 87:13 selectivity over the 2,5-difluoro byproduct. Conversely, slow addition of n-butyllithium (1.05 equiv) at −95°C promoted exclusive lithium-bromine exchange within 15 seconds; subsequent carboxylation with dry CO₂ gas delivered thiazole-4-carboxylic acid in 93% yield after acidic workup. Process safety assessments using a Mettler-Toledo RC1 calorimeter indicated that the Li/Br exchange exhibits an adiabatic temperature rise of 18.7°C and a maximum pressure rate of 1.2 bar/min, necessitating jacket temperature control within a ±3°C band and a rupture disc rated at 5 barg. This dual-mode reactivity is exploited in the synthesis of pyridine-thiazole ligands for asymmetric catalysis: the 4-carboxylate derivative is converted to the corresponding Weinreb amide via CDI activation, then treated with 2-pyridylmagnesium bromide to install the chelating pyridyl ketone unit without detectable racemization at the stereogenic center introduced in a subsequent Noyori reduction step (e.e. >99.5%, determined by chiral supercritical fluid chromatography using a Chiralpak IG-3 column). The finished catalyst, a C₂-symmetric bis(thiazole) diamine, achieves 96% conversion in the asymmetric Henry reaction between nitromethane and 2-chlorobenzaldehyde with an enantiomeric ratio of 98.5:1.5, as validated under the standardized conditions prescribed by the ACS GCI Pharmaceutical Roundtable.

Scaling the thiazole-4-carboxylic acid route from gram to multi-kilogram quantities demands a reevaluation of quench protocol. Direct aqueous quench on the lithio-thiazole at −78°C led to a violent exotherm exceeding 200 W/kg in the 100 L vessel, with localized hot spots catalyzing ring-opening to form β-mercapto-α-bromoacrylonitrile derivatives—a thermally unstable side product that accumulated to 2.8 area% when the internal temperature reached −40°C within the quench zone. Substituting the quench medium with a pre-cooled (−60°C) solution of isopropanol in THF (1:1 v/v) reduced the exotherm to 48 W/kg and suppressed ring-opening below the 0.05% detection limit. This modification was essential for meeting the purity specifications required for the subsequent amide coupling step: any residual ring-opened impurity acted as a chain stopper in the polycondensation with 4,4’-oxydianiline, limiting the number-average molecular weight of the final polybenzothiazole film to Mn < 8,500 Da versus the target of ≥25,000 Da required for flexible OLED substrate applications.

SDHI fungicide fragment assembly via 4-bromothiazole-2-carbonitrile

Within the succinate dehydrogenase inhibitor (SDHI) class of crop protection agents, the thiazole-4-carboxamide motif appears in multiple commercial products, and 4-bromothiazole serves as the entry point to the 2-cyano derivative that enables late-stage diversification. The cyanation of 4-bromothiazole using 1.2 equiv of zinc cyanide, 4 mol% Pd₂(dba)₃, and 8 mol% 1,1’-bis(diphenylphosphino)ferrocene (dppf) in N,N-dimethylacetamide at 110°C proceeds with a reaction calorimetry heat flow of −115 kJ/mol, requiring a programmable temperature ramp of 2°C/min to avoid overshoot. The resulting 4-cyano-thiazole intermediate is hydrolyzed under controlled acidic conditions (sulfuric acid 70%, 65°C, 8 h) to the carboxamide, which is further condensed with 1.05 equiv of 2-trifluoromethylaniline using propylphosphonic anhydride (T3P, 50% in ethyl acetate, 1.5 equiv) and N-methylmorpholine (2.0 equiv) in acetonitrile at 40°C. The technical-grade active ingredient is crystallized from ethanol/water to a polymorphic Form A that exhibits a melting endotherm of 168.3°C (DSC, 10°C/min) and a characteristic PXRD peak at 2θ = 12.8°, identical to the reference standard approved under EPA Reg. No. 83529-4 for a commercial SDHI formulation. Formulated as a 20% suspension concentrate (SC), the product passes CIPAC MT 46.3 for wet sieve retention (≤0.1% on 75 µm), and the accelerated storage stability test at 54°C for 14 days shows ≤2.1% active ingredient degradation.

Environmental fate and mammalian toxicology data packages generated for submissions to the European Food Safety Authority (EFSA) under Regulation (EC) No. 1107/2009 require that the technical material contains no more than 0.1% of the des-bromo dimer impurity, which forms if the cyanation batch temperature exceeds 118°C due to palladium-black-catalyzed homocoupling. A dedicated process analytical technology (PAT) loop with an inline ReactIR 15 probe monitoring the nitrile stretch at 2234 cm⁻¹ relative to the C–Br absorbance at 598 cm⁻¹ was implemented on the 200 L Hastelloy reactor to maintain the dimer at <0.05%. The finished SC formulation is packaged in fluorinated HDPE containers compliant with UN 1H1/Y1.9/100 standards, and the label indicates the mandatory 48‑hour re-entry interval and the maximum application rate of 0.5 kg a.i./ha per season for use on cereals and turfgrass.

Regulatory starting material definitions for the pesticide active substance require 4-bromothiazole to be manufactured under a Qualified Person (QP) declaration confirming compliance with Good Manufacturing Practice for active substances (EU Regulation No. 1107/2009 Annex II, point 3.3). The supplier specification includes a limit for benzene content of ≤2 ppm, determined by headspace GC-MS with a dimethylpolysiloxane column (DB-624, 30 m × 0.32 mm × 1.8 µm) and a trap-and-purge pre-concentration step using a Tenax TA adsorbent. Batch history data over 28 commercial lots demonstrated a mean benzene value of 0.7 ppm with a process capability index Cpk of 1.87, confirming the robustness of the 4-bromothiazole source for this sensitive agrochemical supply chain.

Bridging the gap between small-molecule homogeneous catalysis and recoverable polymer-supported systems, the thiazole ring has been incorporated into poly(ionic liquid) backbones via free-radical copolymerization of 4-bromothiazole-derived vinyl monomers. 4-Bromothiazole is first converted to 4-(4-vinylphenyl)thiazole through a Negishi coupling with 4-vinylphenylzinc bromide (prepared from 4-bromostyrene and Rieke zinc) catalyzed by Pd-PEPPSI-IPent (0.8 mol%) in THF/NMP (3:1) at 50°C for 4 h. After passing the crude product through a plug of activated carbon (Darco G-60, 0.5 wt% relative to monomer) to remove residual palladium, the monomer is polymerized in the presence of divinylbenzene (8 mol%) and AIBN (1.5 mol%) at 70°C in acetonitrile to yield crosslinked beads with a BET surface area of 410 m²/g and a pore volume of 0.58 cm³/g (measured by nitrogen adsorption at 77 K on a Micromeritics ASAP 2020). Post-synthetic quaternization of the thiazole nitrogen with methyl iodide (5 equiv, 40°C, 24 h in DMF) generates the thiazolium iodide resin, which upon deprotonation with potassium tert-butoxide (1.2 equiv) in THF generates the free NHC in situ. This polymer-bound NHC coordinates to [Ir(COD)Cl]₂ (0.25 mol% Ir) to produce a heterogeneous catalyst for hydrogen isotope exchange (HIE) that introduces deuterium into drug-like substrates with an ortho‑directing functional group. The catalyst retains 92% activity after ten consecutive cycles in a continuous-flow packed-bed reactor (internal diameter 4 mm, bed length 100 mm, flow rate 0.1 mL/min), with iridium leaching below 0.8 ppm as determined by ICP-OES. This application places the 4-bromothiazole supply squarely within GMP envelope for API radiolabeling where deuterated internal standards must comply with the ICH M7 guideline for mutagenic impurities, particularly the requirement that the mutagenic risk from residual bromothiazole monomer be assessed via the Ames MPF assay (OECD TG 471) with a limit of ≤1.5 µg/day specific to the clinical dose.

When anhydrous protocols eliminate ring-opening side reactions during formylation at the 2-position

Vilsmeier-Haack formylation of 4-bromothiazole using the premixed complex prepared from phosphorus oxychloride (1.3 equiv) and anhydrous DMF (1.25 equiv) in 1,2-dichloroethane at 0°C to 5°C proceeds smoothly to 4-bromothiazole-2-carboxaldehyde. However, the presence of adventitious water—introduced either through hygroscopic DMF storage or incomplete reactor drying—triggers a cascade: hydrolysis of the Vilsmeier adduct at the electrophilic C-2 position releases chloride ion, which adds to the electron-deficient C-4 brominated carbon, forming a 2,4-dichloro-thiazole intermediate that further hydrolyzes to the 4-hydroxy derivative with a characteristic UV shift from 268 nm to 312 nm. Karl Fischer titration of the bulk reaction mixture prior to POCl₃ addition must read ≤50 ppm H₂O; failure to meet this threshold resulted in a documented batch (Lot #THZ-0312) where the isolated yield dropped from 78% to 41% and the major impurity (4-hydroxy-2-chlorothiazole) caused a false positive in an Ames fluctuation test performed per OECD TG 471 with Salmonella typhimurium TA1537, delaying a Phase I IND submission by 6 weeks.

The 2-formyl derivative is reduced with sodium borohydride (0.55 equiv relative to aldehyde) in methanol/THF (2:1) at −5°C to the corresponding 4-bromothiazole-2-methanol, a versatile intermediate for the construction of thiazolylmethyl ether prodrugs of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Mitsunobu coupling with a phenolic payload (e.g., 3-cyano-5-hydroxyindazole, 1.1 equiv) using diisopropyl azodicarboxylate (1.4 equiv) and triphenylphosphine (1.4 equiv) in THF at 25°C delivers the ether in 94% crude yield, with residual triphenylphosphine oxide removed by precipitation from MTBE/heptane (1:3) at −20°C. Tight specification on residual phosphine oxide (≤10 ppm) is critical: in vitro CYP3A4 inhibition assays (IC₅₀ shift method with testosterone as probe substrate) show a 4.2-fold increase in inhibitory potency when phosphine oxide is present at 50 ppm, a concentration that could artifactually flag a lead compound as a drug–drug interaction risk. The final prodrug candidate is micronized using a jet mill (Hosokawa Alpine 50 AS) to a D₉₀ of ≤5 µm, blended with lactose monohydrate and croscarmellose sodium, and compressed into tablets with a tensile strength of 1.8 MPa. The dissolution specification (USP Apparatus 2, paddle 50 rpm, 900 mL of pH 6.8 phosphate buffer + 0.5% SLS) requires ≥85% release at 30 min, a parameter directly linked to the crystalline form of the 4-bromothiazole-derived synthon used in the final step.